View Exam | PowerPak

1. All of the following alternatives to frontline therapy treatment with daclatasvir/sofosbuvir are contraindicated in a patient with hepatitis C virus genotype 3 infection, EXCEPT:

A. PEG-IFN/RBV B. Sofosbuvir/RBV C. Sofosbuvir monotherapy D. Telaprevir-, boceprevir-, or simeprevir-based regimens

2. Daclatasvir is contraindicated in combination with:

A. Strong CYP3A inhibitors B. Moderate CYP3A inhibitors C. Strong CYP3A inducers D. Moderate CYP3A inducers

3. RM is a 58-year-old woman with hepatitis C virus genotype 2 infection who failed first-line treatment with direct-acting antiviral agent-based therapy. Resistance-associated variant testing revealed the presence of a polymorphism associated with resistance to ledipasvir, an NS5A protease inhibitor. Which of the following describes the BEST approach to retreatment?

A. Retreatment with ledipasvir monotherapy B. Retreatment with ledipasvir-based combination therapy C. Retreatment with a non-ledipasvir NS5A inhibitor D. Retreatment with an NS3/4A inhibitor

4. Which of the following BEST describes the investigational 3-drug combination of sofosbuvir/velpatasvir/GS-9857?

A. The regimen is effective in only treating patients with hepatitis C virus genotype 3. B. The regimen requires a short treatment duration (6 to 8 weeks). C. The regimen is effective regardless of the presence of resistance polymorphisms. D. The regimen requires weekly viral load testing to monitor for viral breakthrough.

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. All of the following alternatives to frontline therapy treatment with daclatasvir/sofosbuvir are contraindicated in a patient with hepatitis C virus genotype 3 infection, EXCEPT:

2. Daclatasvir is contraindicated in combination with:

4. Which of the following BEST describes the investigational 3-drug combination of sofosbuvir/velpatasvir/GS-9857?

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. All of the following alternatives to frontline therapy treatment with daclatasvir/sofosbuvir are contraindicated in a patient with hepatitis C virus genotype 3 infection, EXCEPT:

2. Daclatasvir is contraindicated in combination with:

4. Which of the following BEST describes the investigational 3-drug combination of sofosbuvir/velpatasvir/GS-9857?

« Return to Activity

Customers who Purchased
this Activity also Purchased